Company Description
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
Valuation
P/E Current
30.13
P/E Ratio (with extraordinary items)
30.13
P/E Ratio (without extraordinary items)
24.87
Price to Sales Ratio
6.28
Price to Book Ratio
28.63
Price to Cash Flow Ratio
23.70
Enterprise Value to EBITDA
20.45
Enterprise Value to Sales
6.81
Total Debt to Enterprise Value
0.10
Efficiency
Revenue/Employee
701,137.00
Income Per Employee
176,963.00
Receivables Turnover
3.94
Total Asset Turnover
0.57
Liquidity
Current Ratio
1.40
Quick Ratio
1.08
Cash Ratio
0.29
Profitability
Gross Margin
77.66
Operating Margin
27.91
Pretax Margin
29.46
Net Margin
25.24
Return on Assets
14.42
Return on Equity
150.18
Return on Total Capital
33.38
Return on Invested Capital
31.65
Capital Structure
Total Debt to Total Equity
294.16
Total Debt to Total Capital
74.63
Total Debt to Total Assets
35.59
Long-Term Debt to Equity
294.01
Long-Term Debt to Total Capital
74.59
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. David A. Ricks | 51 | 1996 | President-Bio Medicines & Senior Vice President |
Ms. Anat Ashkenazi | 47 | 2013 | Chief Financial Officer-Lilly Oncology |
Dr. Timothy J. Garnett | - | 1998 | Chief Medical Officer & VP-Global Medical |
Dr. Aarti S. Shah | 55 | 1994 | Global Brand Leader-Autoimmune Division |
Dr. Daniel M. Skovronsky | 46 | 2018 | Senior VP-Science & Technology Business |
Insider Actions
02/16/2021 |
Jackson Peter Tai Director |
10 | Award at $205.76 per share. | 2,057 |
02/16/2021 |
Ralph Alvarez Director |
53 | Award at $207.76 per share. | 11,011 |
02/08/2021 |
David A. Ricks President & CEO; Director |
130,343 | Award at $205.77 per share. | 26,820,679 |
02/08/2021 |
Stephen F. Fry SVP, HR & Diversity |
26,133 | Award at $205.77 per share. | 5,377,387 |
02/08/2021 |
Daniel M. Skovronsky SVP, CSO, and Pres. LRL |
18,521 | Award at $205.77 per share. | 3,811,066 |
02/08/2021 |
Myles Oneill SVP & Pres., Mfg. Operations |
21,052 | Award at $205.77 per share. | 4,331,870 |
02/08/2021 |
Joshua L. Smiley |
25,409 | Award at $205.77 per share. | 5,228,409 |
02/08/2021 |
Alfonso G. Zulueta SVP & President, Lilly Int l |
29,037 | Award at $205.77 per share. | 5,974,943 |
02/08/2021 |
Melissa Stapleton Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
9,594 | Award at $205.77 per share. | 1,974,157 |
02/08/2021 |
Anne E. White SVP & Pres-Lilly Oncology |
4,718 | Award at $205.77 per share. | 970,822 |
02/08/2021 |
Aarti S. Shah SVP & CIDO |
11,033 | Award at $205.77 per share. | 2,270,260 |
02/08/2021 |
Patrik Jonsson SVP & President Lilly USA |
5,595 | Award at $205.77 per share. | 1,151,283 |
02/08/2021 |
Johna L. Norton Senior VP, Global Quality |
6,040 | Award at $205.77 per share. | 1,242,850 |
02/08/2021 |
Mike Mason Sr. VP & Pres., Lilly Diabetes |
6,350 | Award at $205.77 per share. | 1,306,639 |
02/08/2021 |
Leigh Ann Pusey SVP, Corp. Affairs & Comm. |
10,791 | Award at $205.77 per share. | 2,220,464 |
02/08/2021 |
Anat Ashkenazi SVP & CFO |
7,975 | Award at $205.77 per share. | 1,641,015 |
02/08/2021 |
Donald A. Zakrowski Chief Accounting Officer |
4,247 | Award at $205.77 per share. | 873,905 |
02/08/2021 |
Ilya Yuffa SVP and Pres, Lilly Bio-Meds |
3,536 | Award at $205.77 per share. | 727,602 |
02/01/2021 |
David A. Ricks President & CEO; Director |
33,738 | Derivative/Non-derivative trans. at $207.97 per share. | 7,016,491 |
02/01/2021 |
Stephen F. Fry SVP, HR & Diversity |
6,746 | Derivative/Non-derivative trans. at $207.97 per share. | 1,402,965 |
02/01/2021 |
Myles Oneill SVP & Pres., Mfg. Operations |
5,438 | Derivative/Non-derivative trans. at $207.97 per share. | 1,130,940 |
02/01/2021 |
Joshua L. Smiley |
8,452 | Derivative/Non-derivative trans. at $207.97 per share. | 1,757,762 |
02/01/2021 |
Alfonso G. Zulueta SVP & President, Lilly Int l |
7,490 | Derivative/Non-derivative trans. at $207.97 per share. | 1,557,695 |
02/01/2021 |
Melissa Stapleton Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
2,403 | Derivative/Non-derivative trans. at $207.97 per share. | 499,751 |
02/01/2021 |
Aarti S. Shah SVP & CIDO |
2,780 | Derivative/Non-derivative trans. at $207.97 per share. | 578,156 |
02/01/2021 |
Johna L. Norton Senior VP, Global Quality |
1,529 | Derivative/Non-derivative trans. at $207.97 per share. | 317,986 |
02/01/2021 |
Leigh Ann Pusey SVP, Corp. Affairs & Comm. |
2,854 | Derivative/Non-derivative trans. at $207.97 per share. | 593,546 |
02/01/2021 |
David A. Ricks President & CEO; Director |
75,387 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/01/2021 |
Stephen F. Fry SVP, HR & Diversity |
15,078 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/01/2021 |
Myles Oneill SVP & Pres., Mfg. Operations |
12,146 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/01/2021 |
Joshua L. Smiley |
19,266 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/01/2021 |
Alfonso G. Zulueta SVP & President, Lilly Int l |
16,754 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/01/2021 |
Melissa Stapleton Barnes Chief Eth/Cmpl Ofcr & SVP, ERM |
5,445 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/01/2021 |
Aarti S. Shah SVP & CIDO |
6,282 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/01/2021 |
Johna L. Norton Senior VP, Global Quality |
3,435 | Derivative/Non-derivative trans. at $0 per share. | 0 |
02/01/2021 |
Leigh Ann Pusey SVP, Corp. Affairs & Comm. |
6,282 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/19/2021 |
Jackson Peter Tai Director |
10 | Award at $198.48 per share. | 1,984 |
01/19/2021 |
Ralph Alvarez Director |
55 | Award at $198.48 per share. | 10,916 |
01/15/2021 |
Lilly Endowment, Inc. |
148,766 | Disposition at $191.14 per share. | 28,435,133 |
01/15/2021 |
Lilly Endowment, Inc. |
41,298 | Disposition at $190.49 per share. | 7,866,856 |
01/15/2021 |
Lilly Endowment, Inc. |
24,936 | Disposition at $189.3 per share. | 4,720,384 |
01/13/2021 |
Lilly Endowment, Inc. |
9,722 | Disposition at $187.12 per share. | 1,819,180 |
01/13/2021 |
Lilly Endowment, Inc. |
95,353 | Disposition at $186.47 per share. | 17,780,473 |
01/13/2021 |
Lilly Endowment, Inc. |
104,925 | Disposition at $185.4 per share. | 19,453,095 |
01/11/2021 |
Lilly Endowment, Inc. |
300 | Disposition at $187.46 per share. | 56,238 |
01/11/2021 |
Lilly Endowment, Inc. |
48,871 | Disposition at $187 per share. | 9,138,877 |
01/11/2021 |
Lilly Endowment, Inc. |
42,301 | Disposition at $185.63 per share. | 7,852,334 |
01/11/2021 |
Lilly Endowment, Inc. |
128,528 | Disposition at $184.87 per share. | 23,760,971 |
12/21/2020 |
Jackson Peter Tai Director |
12 | Award at $168.78 per share. | 2,025 |
11/16/2020 |
Kathi P. Seifert Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
Jon Erik Fyrwald Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
Jackson Peter Tai Director |
1,259 | Award at $140.59 per share. | 177,002 |
11/16/2020 |
Ralph Alvarez Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
Michael L. Eskew Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
Katherine Baicker Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
William G. Kaelin Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
Marschall S. Runge Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
Juan Ricardo Luciano Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
Jamere Jackson Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
Carolyn R. Bertozzi Director |
1,245 | Award at $140.59 per share. | 175,034 |
11/16/2020 |
Karen Walker Director |
1,245 | Award at $140.59 per share. | 175,034 |
10/19/2020 |
Jackson Peter Tai Director |
14 | Award at $142.8 per share. | 1,999 |
MarketWatch News on LLY
-
Riell shares jump 31% premarket
- Ciara Linnane
-
Eli Lilly to pay Rigel $125 mln upfront, up to $835 mln in future milestone payments
- Ciara Linnane
-
Eli Lilly and Rigel to codevelop Rigel's treatment for immunological and neurodegenerative diseases
- Ciara Linnane
-
5 Affordable Biopharma Stocks With Growth Potential
- Josh Nathan-Kazis
-
Vir and GSK Will Collaborate on Flu Therapy
- Josh Nathan-Kazis
-
Vir and GSK Will Collaborate on Flu Therapy
- Josh Nathan-Kazis
-
Eli Lilly Executives Enthusiastic About Alzheimer's Drug, Analyst Says
- Josh Nathan-Kazis
-
S&P 500, Dow miss out on new records and snap 6-day win streak
- William Watts
-
Eli Lilly says CFO Smiley had 'inappropriate' personal communications with certain employees
- Ciara Linnane
-
Eli Lilly names Anat Ashkenazi CFO replacing Josh Smiley who is resigning
- Ciara Linnane
-
Biogen’s Alzheimer’s Drug Faces a Big Test
- Josh Nathan-Kazis
-
- Reshma Kapadia
- Loading more headlines...
Other News on LLY
-
Merck Makes Another Move to Beef Up Drug Business
- GuruFocus.com
-
RLFTF: Why Little-Known Relief Therapeutics Is Climbing Today
- InvestorPlace.com
-
Big Pharma Short Percentage Is Below Overall Market
- GuruFocus.com
-
10-K: HALOZYME THERAPEUTICS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Why Piotroski's F-Score No Longer Works
- Seeking Alpha
-
Avidity Biosciences shares soar 18% in afternoon trading
- Seeking Alpha
-
RIGL Stock: Why Rigel Pharmaceuticals Is Climbing Today
- InvestorPlace.com
- Loading more headlines...